Sandwich stem event helps students learn 'real science'

More than 1,500 children have descended on the Sandwich Discovery Park for a hands-on exhibition to inspire a new generation of scientists.Everything from the biggest bubble blowing to catching a sandwich thief is being demonstrated by scientists from different organisations across Kent at a science, technology, engineering and maths (Stem) education event.Pamela Lithgow, from the Canterbury Christchurch University Stem hub, said the event was helping young people understand "real science in the real world".She added: "We welcome everyone to this event but we are particularly keen to see children from deprived areas and also young girls and those who want to be engineers."
"When engineers make things, they often do so to solve their own problems so we need as diverse a range of people making things as possible so that they make all our lives better."The two-day annual jamboree, celebrating its 30th anniversary, was established by members of pharmaceutical giant Pfizer in 1985 and now works with more than 50 schools in Kent.
Teams from businesses such as Southern Water and the Royal Engineers Museum in Medway showed pupils interactive Stem exhibits including making and launching a rocket, and filtering dirty water.Discovery Park is recognized as one of six Life Science Opportunity Zones in the UK by the government, with over 180 companies employing 3,000 people across the 220 acres site.The site was created by Pfizer 70 years ago but was scaled down in 2011.Ruth Wish, assistant head of Minster Church of England Primary School, brought the school's Year Six cohort for the first time this year.She added: "We feel like it's really important to show our pupils there is a massive, huge growing future in Stem as they head towards secondary school and we want them to enjoy science too."

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Daily Mail​

an hour ago

• Daily Mail​

Erectile dysfunction drug Viagra has surprise new health benefit, scientists find - offering new hope to 3million ageing Britons

A surprising new health benefit has emerged from the sex drug Viagra - which means three million ageing Britons can now also enjoy a harder skull. The little blue tablet was found to increase the production of vital bone cells, preventing back pain and fractures in old age. Sildenafil - also known as Viagra - can help human stem cells transform into osteoblasts which help the human skeleton regenerate as it is completely replaced roughly once every 10 years. As humans get older, they lose more bone than is built, increasing the risk of breaks or osteoporosis, which makes bones brittle and painful. Follow-up tests on mice by Peking University also suggested a prevention of bone loss. Dr Menglong Hu and Dr Likun Wu told MailOnline: 'Our findings offer new insights into the physiological effects of the medicine. 'Sildenafil enhanced stem cell osteogenic differentiation and inhibited bone loss — it may usefully treat osteoporosis.' Viagra was invented as a heart drug in the 1980s before being found to help with erectile dysfunction. Some studies suggest it may also help reduce the risk of dementia. However, the have been cautions over the years that the drug could have some negative side effects, in particular if taken too much. A large quantity of the drug could result in a painful, 'uncomfortably and disproportionately large erection' called a priapism which could go on for hours. Some experts also found regularly taking the common drug may raise the risk of three serious eye conditions. Common side effects may include headaches, hot flushes, nausea, indigestion, dizziness and a stuffy nose. Nearly half of men between the ages of 40 and 70 suffer from erectile dysfunction in the UK - this is more than 4.5 million people. Though, reports suggest Viagra is now even becoming increasingly popular with younger individuals in their 20s and 30s. Last year, it emerged Viagra may help prevent dementia by boosting blood flow in the brain. 'This is the first trial to show that sildenafil gets into the blood vessels in the brain in people with this condition, improving blood flow and how responsive these blood vessels are,'Dr Alastair Webb, a neurologist and study author at Oxford University said.

Times

an hour ago

• Times

My famous father — the fraudulent, fantasist scientist

'When I was small,' Joanne Briggs writes touchingly. 'I believed my dad to be the only man who knew all science.' Michael Briggs had all but disappeared from her life in the early 1970s when she was seven after walking out on her mother, but she would correct anyone who showed pity for her as a fatherless child. Dad hadn't gone, she would tell them, he was just in another country being a very famous scientist in the fields of space, and poisons, and having babies. 'Anything you can think of, really, he's an expert in it.' She wasn't the only one to have this inflated view of her father's expertise. Indeed, the scientific establishment shared it, at least for a while. Michael was a Nasa space scientist turned pharmacologist, a renowned specialist in biochemistry, an adviser to the World Health Organisation and a university dean of sciences. He had written papers on topics ranging from human hormones to meteorites and intergalactic travel. The son of a typewriter mechanic from Manchester, he was a self-made man, bouncing round the world from Australia to Pasadena, taking on ever more prestigious positions, pushing at the boundaries of the scientific imagination and 'grabbing hold of everything the Jet Age had to offer'.

The Independent

3 hours ago

• The Independent

Weight loss jab could be used to treat migraines

Weight loss jabs could cut the number of migraines sufferers experience by half, research suggests. The drugs, similar to Ozempic and Wegovy, also known as GLP-1 receptor agonists, work by mimicking the natural hormone which regulates blood sugar, appetite and digestion. Researchers have discovered, GLP-1 drug liraglutide, commonly used to treat diabetes, has the potential to significantly reduce migraine frequency. Migraines affect approximately 6 million people in the UK, according to the NHS. Attacks can last for three days causing pain, nausea, vomiting, dizziness and sensitivity to light, sound and smells. Researchers at the Headache Centre of the University of Naples gave 26 adults with obesity and chronic migraines the drug liraglutide. The study presented at the European Academy of Neurology (EAN) Congress 2025, found those who had the drug reported an average of 11 fewer headache days per month. Participants also experienced meaningful improvements in quality of life, work, study, and social functioning within just two weeks of taking the drug. 'Most patients felt better within the first two weeks and reported quality of life improved significantly', said lead researcher Dr Simone Braca. 'The benefit lasted for the full three-month observation period, even though weight loss was modest and statistically non-significant.' Growing evidence has linked subtle increases in intracranial pressure to migraine attacks. It's caused by a rise in the pressure of cerebrospinal fluid – which surrounds the brain and spinal cord. This increase in pressure can happen because of a severe head injury, stroke, a brain tumour or high blood pressure. But GLP-1-receptor agonists such as liraglutide reduce cerebrospinal fluid secretion and have already proved effective in treating idiopathic intracranial hypertension (IIH). Patients in the study were screened to exclude papilledema (optic disc swelling resulting from increased intracranial pressure) and sixth nerve palsy, ruling out IIH. Dr Braca and colleagues believe GLP-1 drugs may reduce the release of CGRP (calcitonin gene-related peptide), a key molecule behind migraines. 'We think that, by modulating cerebrospinal fluid pressure and reducing intracranial venous sinuses compression, these drugs produce a decrease in the release of calcitonin gene-related peptide (CGRP), a key migraine-promoting peptide', Dr Braca said. 'That would pose intracranial pressure control as a brand-new, pharmacologically targetable pathway.' Given liraglutide's established use in type 2 diabetes and obesity, it may represent a promising case of drug repurposing in neurology, study authors said.